ADMA Biologics Inc
NASDAQ:ADMA

Watchlist Manager
ADMA Biologics Inc Logo
ADMA Biologics Inc
NASDAQ:ADMA
Watchlist
Price: 21.18 USD -0.56% Market Closed
Market Cap: 5B USD
Have any thoughts about
ADMA Biologics Inc?
Write Note

Intrinsic Value

The intrinsic value of one ADMA stock under the Base Case scenario is 8.63 USD. Compared to the current market price of 21.18 USD, ADMA Biologics Inc is Overvalued by 59%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ADMA Intrinsic Value
8.63 USD
Overvaluation 59%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
ADMA Biologics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for ADMA cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about ADMA?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about ADMA Biologics Inc

Provide an overview of the primary business activities
of ADMA Biologics Inc.

What unique competitive advantages
does ADMA Biologics Inc hold over its rivals?

What risks and challenges
does ADMA Biologics Inc face in the near future?

Has there been any significant insider trading activity
in ADMA Biologics Inc recently?

Summarize the latest earnings call
of ADMA Biologics Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for ADMA Biologics Inc.

Provide P/S
for ADMA Biologics Inc.

Provide P/E
for ADMA Biologics Inc.

Provide P/OCF
for ADMA Biologics Inc.

Provide P/FCFE
for ADMA Biologics Inc.

Provide P/B
for ADMA Biologics Inc.

Provide EV/S
for ADMA Biologics Inc.

Provide EV/GP
for ADMA Biologics Inc.

Provide EV/EBITDA
for ADMA Biologics Inc.

Provide EV/EBIT
for ADMA Biologics Inc.

Provide EV/OCF
for ADMA Biologics Inc.

Provide EV/FCFF
for ADMA Biologics Inc.

Provide EV/IC
for ADMA Biologics Inc.

Show me price targets
for ADMA Biologics Inc made by professional analysts.

What are the Revenue projections
for ADMA Biologics Inc?

How accurate were the past Revenue estimates
for ADMA Biologics Inc?

What are the Net Income projections
for ADMA Biologics Inc?

How accurate were the past Net Income estimates
for ADMA Biologics Inc?

What are the EPS projections
for ADMA Biologics Inc?

How accurate were the past EPS estimates
for ADMA Biologics Inc?

What are the EBIT projections
for ADMA Biologics Inc?

How accurate were the past EBIT estimates
for ADMA Biologics Inc?

Compare the revenue forecasts
for ADMA Biologics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of ADMA Biologics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of ADMA Biologics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of ADMA Biologics Inc compared to its peers.

Compare the P/E ratios
of ADMA Biologics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing ADMA Biologics Inc with its peers.

Analyze the financial leverage
of ADMA Biologics Inc compared to its main competitors.

Show all profitability ratios
for ADMA Biologics Inc.

Provide ROE
for ADMA Biologics Inc.

Provide ROA
for ADMA Biologics Inc.

Provide ROIC
for ADMA Biologics Inc.

Provide ROCE
for ADMA Biologics Inc.

Provide Gross Margin
for ADMA Biologics Inc.

Provide Operating Margin
for ADMA Biologics Inc.

Provide Net Margin
for ADMA Biologics Inc.

Provide FCF Margin
for ADMA Biologics Inc.

Show all solvency ratios
for ADMA Biologics Inc.

Provide D/E Ratio
for ADMA Biologics Inc.

Provide D/A Ratio
for ADMA Biologics Inc.

Provide Interest Coverage Ratio
for ADMA Biologics Inc.

Provide Altman Z-Score Ratio
for ADMA Biologics Inc.

Provide Quick Ratio
for ADMA Biologics Inc.

Provide Current Ratio
for ADMA Biologics Inc.

Provide Cash Ratio
for ADMA Biologics Inc.

What is the historical Revenue growth
over the last 5 years for ADMA Biologics Inc?

What is the historical Net Income growth
over the last 5 years for ADMA Biologics Inc?

What is the current Free Cash Flow
of ADMA Biologics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for ADMA Biologics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
ADMA Biologics Inc

Current Assets 318.2m
Cash & Short-Term Investments 86.7m
Receivables 50.1m
Other Current Assets 181.3m
Non-Current Assets 72.4m
PP&E 62.6m
Intangibles 4m
Other Non-Current Assets 5.8m
Current Liabilities 44.9m
Accounts Payable 16m
Accrued Liabilities 25.4m
Other Current Liabilities 3.5m
Non-Current Liabilities 113.8m
Long-Term Debt 101.3m
Other Non-Current Liabilities 12.5m
Efficiency

Earnings Waterfall
ADMA Biologics Inc

Revenue
382.8m USD
Cost of Revenue
-195.5m USD
Gross Profit
187.3m USD
Operating Expenses
-98.6m USD
Operating Income
88.7m USD
Other Expenses
-20.6m USD
Net Income
68.1m USD

Free Cash Flow Analysis
ADMA Biologics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

In its third quarter, ADMA Biologics achieved outstanding results, with revenues soaring 78% year-over-year to $119.8 million. Adjusted EBITDA surged 256% to $45.4 million, and net income skyrocketed 1,300% to $35.9 million. The company has raised its revenue guidance to over $415 million for 2024 and $465 million for 2025, expecting adjusted EBITDA to exceed $160 million and $215 million, respectively. The demand for ASCENIV reinforces expectations for strong growth, with potential for it to reach $1 billion in annual revenue. Strategic initiatives like plasma donor retention programs and enhanced production efficiencies are expected to bolster earnings further.

What is Earnings Call?
Fundamental Scores

ADMA Profitability Score
Profitability Due Diligence

ADMA Biologics Inc's profitability score is 45/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
ROE is Increasing
ROIC is Increasing
Exceptional ROE
45/100
Profitability
Score

ADMA Biologics Inc's profitability score is 45/100. The higher the profitability score, the more profitable the company is.

ADMA Solvency Score
Solvency Due Diligence

ADMA Biologics Inc's solvency score is 71/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Low D/E
Long-Term Solvency
71/100
Solvency
Score

ADMA Biologics Inc's solvency score is 71/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ADMA Price Targets Summary
ADMA Biologics Inc

Wall Street analysts forecast ADMA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ADMA is 23.91 USD with a low forecast of 17.4 USD and a high forecast of 27.3 USD.

Lowest
Price Target
17.4 USD
18% Downside
Average
Price Target
23.91 USD
13% Upside
Highest
Price Target
27.3 USD
29% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for ADMA?

Click here to dive deeper.

Dividends

ADMA Biologics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for ADMA is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

ADMA Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

ADMA Biologics Inc Logo
ADMA Biologics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

5B USD

Dividend Yield

0%

Description

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The company is headquartered in Ramsey, New Jersey and currently employs 527 full-time employees. The company went IPO on 2013-10-17. The firm is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include ADMA BioManufacturing and Plasma Collection Centers. The Company’s ADMA BioManufacturing segment reflects its immune globulin manufacturing and development operations in Florida. The Plasma Collection Centers segment consists of approximately three plasma collection facilities. Its products include BIVIGAM, ASCENIV and Nabi-HB. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons.

Contact

NEW JERSEY
Ramsey
C/O Adma Biologics, Inc., 465 State Route 17
+12014785552.0
www.admabiologics.com

IPO

2013-10-17

Employees

527

Officers

Co-Founder, President, CEO & Director
Mr. Adam S. Grossman
Co-Founder & Vice Chairman of the Board
Dr. Jerrold B. Grossman D.P.S., Ph.D.
CFO & Treasurer
Mr. Brad Tade
COO & Senior VP of Compliance
Ms. Kaitlin Kestenberg
Vice President of Marketing & Corporate Development
Mr. Drew Pantello
Executive Director of Sales
Mr. John Hafl
Show More
Vice President of Human Resources
Ms. Cindy Petersen
Senior Director of Business Development & Corporate Strategy
Mr. Skyler Bloom
Show Less

See Also

Discover More
What is the Intrinsic Value of one ADMA stock?

The intrinsic value of one ADMA stock under the Base Case scenario is 8.63 USD.

Is ADMA stock undervalued or overvalued?

Compared to the current market price of 21.18 USD, ADMA Biologics Inc is Overvalued by 59%.

Back to Top